Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapentadol PR in Cancer Pain
NCT00805142Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tapentadol in cancer pain (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants With Sustained Pain Control for 5 Day Fixed Dose Phase. Started Nov 2008; status: completed.
02
Drugs
tapentadol
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00805142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805142.